v3.26.1
Sale of Future IMDELLTRA® Royalties - Schedule of Royalty Sale Liability Activity (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2026
USD ($)
Royalty Financing Obligation [Roll Forward]  
Balance at December 31, 2025 $ 3,827,379
Balance at June 30, 2026 4,001,617
Royalty Payments  
Royalty Financing Obligation [Roll Forward]  
Balance at December 31, 2025 906,956
Debt portion of royalties recognized and settled to Royalty Pharma (2,556)
Accretion of liability 1,913
Balance at June 30, 2026 $ 906,313